QJECT Trademark

Trademark Overview


On Wednesday, June 3, 2020, a trademark application was filed for QJECT with the United States Patent and Trademark Office. The USPTO has given the QJECT trademark a serial number of 88946836. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, January 1, 2024. This trademark is owned by Bristol-Myers Squibb Company. The QJECT trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
qject

General Information


Serial Number88946836
Word MarkQJECT
Filing DateWednesday, June 3, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, January 1, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 30, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, June 24, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events


Event DateEvent Description
Tuesday, January 2, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, January 1, 2024ABANDONMENT - NO USE STATEMENT FILED
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, May 17, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 15, 2023SOU EXTENSION 4 GRANTED
Monday, May 15, 2023SOU EXTENSION 4 FILED
Monday, May 15, 2023SOU TEAS EXTENSION RECEIVED
Friday, November 11, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 9, 2022SOU EXTENSION 3 GRANTED
Wednesday, November 9, 2022SOU EXTENSION 3 FILED
Wednesday, November 9, 2022SOU TEAS EXTENSION RECEIVED
Friday, May 13, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, May 11, 2022SOU EXTENSION 2 GRANTED
Wednesday, May 11, 2022SOU EXTENSION 2 FILED
Wednesday, May 11, 2022SOU TEAS EXTENSION RECEIVED
Thursday, November 18, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 16, 2021SOU EXTENSION 1 GRANTED
Tuesday, November 16, 2021SOU EXTENSION 1 FILED
Tuesday, November 16, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, May 25, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 30, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 30, 2021PUBLISHED FOR OPPOSITION
Wednesday, March 10, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 2, 2021ASSIGNED TO EXAMINER
Sunday, February 21, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, February 19, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, February 18, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, February 18, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, August 31, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, August 31, 2020NON-FINAL ACTION E-MAILED
Monday, August 31, 2020NON-FINAL ACTION WRITTEN
Monday, August 31, 2020ASSIGNED TO EXAMINER
Wednesday, June 24, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, June 6, 2020NEW APPLICATION ENTERED